{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:09:54Z","timestamp":1794373794465,"version":"4.9.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["PJS-186324 and PJT \u2013 169129"],"award-info":[{"award-number":["PJS-186324 and PJT \u2013 169129"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["Project Grant"],"award-info":[{"award-number":["Project Grant"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Extracellular regulated kinase (ERK) signaling is a major driver of cancer development. Mutations accumulated in oncogenes upstream of ERK can promote and sustain tumorigenesis by providing a sustained proliferative signal, helping cells resist death, and inducing angiogenesis. Therapeutic strategies for cancers with dysregulated ERK signaling have focused on inhibiting upstream-mutated oncogenes as a means of depriving tumors of these essential survival cues. While these strategies have demonstrated initial clinical success in patients, they also represent an incomplete understanding of the more nuanced role ERK signaling plays in tumor cell homeostasis. It is now understood that increased ERK signaling can also function as a tumor suppressor by inducing proliferative arrest outside of the framework of oncogene-induced senescence. In this review, we highlight current research describing the vulnerability of cancer cells to ERK hyperactivation induced toxicity and offer insight on how ERK rewiring may be leveraged for the development of new therapeutic strategies for patients.<\/jats:p>","DOI":"10.1007\/s00018-026-06084-6","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T23:06:01Z","timestamp":1774134361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability"],"prefix":"10.1007","volume":"83","author":[{"given":"Dylan A.","family":"Farnsworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Naznin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-3408","authenticated-orcid":false,"given":"William W.","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"10","key":"6084_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M (2020) ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol 21(10):607\u2013632","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"14","key":"6084_CR2","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL (2020) The frequency of Ras mutations in. Cancer\u2019Cancer Res 80(14):2969\u20132974","journal-title":"Cancer\u2019Cancer Res"},{"issue":"7","key":"6084_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14(7):455\u2013467","journal-title":"Nat Rev Cancer"},{"key":"6084_CR4","unstructured":"Sanchez-Vega F, Mina M, Armenia J et al (2018) \u2018Oncogenic Signaling Pathways in The Cancer Genome Atlas\u2019Cell, 173, (2), pp. 321\u2013337.e10"},{"issue":"23","key":"6084_CR5","first-page":"8132","volume":"63","author":"T Ikenoue","year":"2003","unstructured":"Ikenoue T, Hikiba Y, Kanai F et al (2003) Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. \u2019Cancer Res 63(23):8132\u20138137","journal-title":"\u2019Cancer Res"},{"key":"6084_CR6","doi-asserted-by":"crossref","unstructured":"Wan PTC, Garnett MJ, Roe SM et al (2004) \u2018Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF\u2019Cell, 116, (6), pp. 855\u2013867","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"6084_CR7","doi-asserted-by":"crossref","unstructured":"Hoshino R, Chatani Y, Yamori T et al (1999) Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors\u2019Oncogene. 18(3):813\u2013822","DOI":"10.1038\/sj.onc.1202367"},{"issue":"7","key":"6084_CR8","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1128\/MCB.16.7.3923","volume":"16","author":"R Khosravi-Far","year":"1996","unstructured":"Khosravi-Far R, White MA, Westwick JK et al (1996) Oncogenic Ras activation of Raf\/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 16(7):3923\u20133933","journal-title":"Mol Cell Biol"},{"issue":"5676","key":"6084_CR9","first-page":"1497","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. \u2019Science 304(5676):1497\u20131500","journal-title":"\u2019Science"},{"issue":"6","key":"6084_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.onc.1209843","volume":"26","author":"M Marzec","year":"2007","unstructured":"Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA (2007) Oncogenic tyrosine kinase NPM\/ALK induces activation of the MEK\/ERK signaling pathway independently of c-Raf. Oncogene 26(6):813\u2013821","journal-title":"Oncogene"},{"issue":"1","key":"6084_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jhep.2007.08.018","volume":"48","author":"KJ Schmitz","year":"2008","unstructured":"Schmitz KJ, Wohlschlaeger J, Lang H et al (2008) Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48(1):83\u201390","journal-title":"J Hepatol"},{"key":"6084_CR12","doi-asserted-by":"crossref","unstructured":"Cowley S, Paterson H, Kemp P, Marshall CJ (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells\u2019Cell. 77(6):841\u2013852","DOI":"10.1016\/0092-8674(94)90133-3"},{"key":"6084_CR13","doi-asserted-by":"crossref","unstructured":"Mansour SJ, Matten WT, Hermann AS et al (1994) \u2018Transformation of mammalian cells by constitutively active MAP kinase kinase\u2019Science, 265, (5174), pp. 966\u2013970","DOI":"10.1126\/science.8052857"},{"issue":"23","key":"6084_CR14","doi-asserted-by":"publisher","first-page":"13585","DOI":"10.1074\/jbc.270.23.13585","volume":"270","author":"L Pang","year":"1995","unstructured":"Pang L, Sawada T, Decker SJ, Saltiel AR (1995) Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor \u2217. J Biol Chem 270(23):13585\u201313588","journal-title":"J Biol Chem"},{"issue":"20","key":"6084_CR15","doi-asserted-by":"publisher","first-page":"11335","DOI":"10.1073\/pnas.96.20.11335","volume":"96","author":"JH Wright","year":"1999","unstructured":"Wright JH, Munar E, Jameson DR et al (1999) Mitogen-activated protein kinase kinase activity is required for the G2\/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci 96(20):11335\u201311340","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"6084_CR16","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1073\/pnas.92.17.7686","volume":"92","author":"DT Dudley","year":"1995","unstructured":"Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92(17):7686\u20137689","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6084_CR17","doi-asserted-by":"crossref","unstructured":"Solit DB, Garraway LA, Pratilas CA et al (2006) BRAF mutation predicts sensitivity to MEK inhibition\u2019Nature. 439(7074):358\u2013362","DOI":"10.1038\/nature04304"},{"issue":"5","key":"6084_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin AG, Bleam MR, Groy A et al (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17(5):989\u20131000","journal-title":"Clin Cancer Res"},{"issue":"7781","key":"6084_CR19","first-page":"217","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY et al (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. \u2019Nature 575(7781):217\u2013223","journal-title":"\u2019Nature"},{"issue":"3","key":"6084_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","volume":"19","author":"R Barbosa","year":"2021","unstructured":"Barbosa R, Acevedo LA, Marmorstein R (2021) The MEK\/ERK network as a therapeutic target in human cancer. Mol Cancer Res 19(3):361\u2013374","journal-title":"Mol Cancer Res"},{"issue":"7","key":"6084_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20(7):551\u2013569","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"6084_CR22","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877\u20131888","journal-title":"N Engl J Med"},{"issue":"25","key":"6084_CR23","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK et al (2021) Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 384(25):2371\u20132381","journal-title":"N Engl J Med"},{"issue":"2","key":"6084_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-Mutated advanced Non\u2013Small-Cell lung cancer. N Engl J Med 378(2):113\u2013125","journal-title":"N Engl J Med"},{"issue":"1","key":"6084_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2018) Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013Mutant anaplastic thyroid cancer. J Clin Oncol 36(1):7\u201313","journal-title":"J Clin Oncol"},{"issue":"7","key":"6084_CR26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus Trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. \u2019Lancet Oncol 17(7):984\u2013993","journal-title":"\u2019Lancet Oncol"},{"issue":"1","key":"6084_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","volume":"277","author":"S Cagnol","year":"2010","unstructured":"Cagnol S, Chambard J-C (2010) ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence. FEBS J 277(1):2\u201321","journal-title":"FEBS J"},{"key":"6084_CR28","doi-asserted-by":"crossref","unstructured":"Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK\/MAPK mitogenic signaling\u2019Genes Dev. 12(19):3008\u20133019","DOI":"10.1101\/gad.12.19.3008"},{"issue":"10","key":"6084_CR29","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1128\/MCB.22.10.3389-3403.2002","volume":"22","author":"W Wang","year":"2002","unstructured":"Wang W, Chen JX, Liao R et al (2002) Sequential activation of the MEK-Extracellular Signal-Regulated kinase and MKK3\/6-p38 Mitogen-Activated protein kinase pathways mediates oncogenic ras-Induced premature senescence. Mol Cell Biol 22(10):3389\u20133403","journal-title":"Mol Cell Biol"},{"issue":"7051","key":"6084_CR30","first-page":"720","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou C, Vredeveld LCW, Soengas MS et al (2005) BRAFE600-associated senescence-like cell cycle arrest of human Naevi. \u2019Nature 436(7051):720\u2013724","journal-title":"\u2019Nature"},{"issue":"12","key":"6084_CR31","first-page":"1664","volume":"53","author":"T Ito","year":"2021","unstructured":"Ito T, Young MJ, Li R et al (2021) Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. \u2019Nat Genet 53(12):1664\u20131672","journal-title":"\u2019Nat Genet"},{"key":"6084_CR32","doi-asserted-by":"crossref","unstructured":"Unni AM, Harbourne B, Oh MH et al (2018) Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells\u2019eLife. 7:e33718","DOI":"10.7554\/eLife.33718"},{"issue":"7436","key":"6084_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur M, Salangsang F, Landman AS et al (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494(7436):251\u2013255","journal-title":"Nature"},{"issue":"7675","key":"6084_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature24037","volume":"550","author":"X Kong","year":"2017","unstructured":"Kong X, Kuilman T, Shahrabi A et al (2017) Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature 550(7675):270\u2013274","journal-title":"Nature"},{"key":"6084_CR35","doi-asserted-by":"crossref","unstructured":"Sale MJ, Balmanno K, Saxena J et al (2019) \u2018MEK1\/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance\u2019Nat. Commun., 10, (1), p. 2030","DOI":"10.1038\/s41467-019-09438-w"},{"issue":"1","key":"6084_CR36","first-page":"1","volume":"6","author":"DA Farnsworth","year":"2022","unstructured":"Farnsworth DA, Inoue Y, Johnson FD et al (2022) MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. Npj Precis Oncol 6(1):1\u201315","journal-title":"Npj Precis Oncol"},{"issue":"5600","key":"6084_CR37","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298(5600):1911\u20131912","journal-title":"Science"},{"issue":"Pt 16","key":"6084_CR38","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1242\/jcs.02470","volume":"118","author":"M Qi","year":"2005","unstructured":"Qi M, Elion EA (2005) Map kinase pathways. J Cell Sci 118(Pt 16):3569\u20133572","journal-title":"J Cell Sci"},{"issue":"3","key":"6084_CR39","first-page":"1997","volume":"19","author":"Y-J Guo","year":"2020","unstructured":"Guo Y-J, Pan W-W, Liu S-B, Shen Z-F, Xu Y, Hu L-L (2020) ERK\/MAPK signaling pathway and tumorigenesis. Exp Ther Med 19(3):1997\u20132007","journal-title":"Exp Ther Med"},{"key":"6084_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/bs.acr.2018.02.004","volume":"138","author":"ST Eblen","year":"2018","unstructured":"Eblen ST (2018) Extracellular-regulated kinases: signaling from Ras to ERK substrates to control biological outcomes. Adv Cancer Res 138:99\u2013142","journal-title":"Adv Cancer Res"},{"issue":"2","key":"6084_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"R Roskoski","year":"2012","unstructured":"Roskoski R (2012) ERK1\/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66(2):105\u2013143","journal-title":"Pharmacol Res"},{"key":"6084_CR42","doi-asserted-by":"crossref","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signaling pathways in cancer\u2019Oncogene. 26(22):3279\u20133290","DOI":"10.1038\/sj.onc.1210421"},{"issue":"2","key":"6084_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1385\/MB:31:2:151","volume":"31","author":"H Rubinfeld","year":"2005","unstructured":"Rubinfeld H, Seger R (2005) The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 31(2):151\u2013174","journal-title":"Mol Biotechnol"},{"issue":"3","key":"6084_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20082234","volume":"418","author":"KI Patterson","year":"2009","unstructured":"Patterson KI, Brummer T, O\u2019Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418(3):475\u2013489","journal-title":"Biochem J"},{"issue":"1","key":"6084_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbamcr.2018.09.002","volume":"1866","author":"O-M Seternes","year":"2019","unstructured":"Seternes O-M, Kidger AM, Keyse SM (2019) Dual-specificity MAP kinase phosphatases in health and disease. Biochim Biophys Acta Mol Cell Res 1866(1):124\u2013143","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"11","key":"6084_CR46","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrm1743","volume":"6","author":"W Kolch","year":"2005","unstructured":"Kolch W (2005) Coordinating ERK\/MAPK signaling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6(11):827\u2013837","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6084_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.cellbio.19.111401.091942","volume":"19","author":"DK Morrison","year":"2003","unstructured":"Morrison DK, Davis RJ (2003) Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 19:91\u2013118","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"6084_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1385\/MB:29:1:57","volume":"29","author":"D Chuderland","year":"2005","unstructured":"Chuderland D, Seger R (2005) Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol 29(1):57\u201374","journal-title":"Mol Biotechnol"},{"issue":"2","key":"6084_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0092-8674(95)90401-8","volume":"80","author":"CJ Marshall","year":"1995","unstructured":"Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2):179\u2013185","journal-title":"Cell"},{"key":"6084_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ceb.2016.01.007","volume":"39","author":"E Wainstein","year":"2016","unstructured":"Wainstein E, Seger R (2016) The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles. Curr Opin Cell Biol 39:15\u201320","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"6084_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/biof.52","volume":"35","author":"Z Yao","year":"2009","unstructured":"Yao Z, Seger R (2009) The ERK signaling cascade\u2013views from different subcellular compartments. BioFactors 35(5):407\u2013416","journal-title":"BioFactors"},{"issue":"8","key":"6084_CR52","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"J-C Chambard","year":"2007","unstructured":"Chambard J-C, Lefloch R, Pouyss\u00e9gur J, Lenormand P (2007) Erk implication in cell cycle regulation. Biochim Biophys Acta 1773(8):1299\u20131310","journal-title":"Biochim Biophys Acta"},{"issue":"28","key":"6084_CR53","doi-asserted-by":"publisher","first-page":"20293","DOI":"10.1016\/S0021-9258(19)88700-8","volume":"267","author":"H Tamemoto","year":"1992","unstructured":"Tamemoto H, Kadowaki T, Tobe K et al (1992) Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem 267(28):20293\u201320297","journal-title":"J Biol Chem"},{"issue":"22","key":"6084_CR54","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","volume":"26","author":"S Meloche","year":"2007","unstructured":"Meloche S, Pouyss\u00e9gur J (2007) The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26(22):3227\u20133239","journal-title":"Oncogene"},{"issue":"11","key":"6084_CR55","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1093\/emboj\/cdg273","volume":"22","author":"A Soloaga","year":"2003","unstructured":"Soloaga A, Thomson S, Wiggin GR et al (2003) MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-. EMBO J 22(11):2788\u2013279714\u2019","journal-title":"EMBO J"},{"issue":"18","key":"6084_CR56","doi-asserted-by":"publisher","DOI":"10.1242\/dev.199767","volume":"148","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Goto Y, Kondo Y, Aoki K (2021) Shedding light on developmental ERK signaling with genetically encoded biosensors. Development 148(18):dev199767","journal-title":"Development"},{"issue":"12","key":"6084_CR57","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.devcel.2021.05.007","volume":"56","author":"PA Gagliardi","year":"2021","unstructured":"Gagliardi PA, Dobrzy\u0144ski M, Jacques M-A et al (2021) Collective ERK\/Akt activity waves orchestrate epithelial homeostasis by driving apoptosis-induced survival. \u2019Dev Cell 56(12):1712\u20131726e6","journal-title":"\u2019Dev Cell"},{"key":"6084_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2024.102368","volume":"88","author":"PA Gagliardi","year":"2024","unstructured":"Gagliardi PA, Pertz O (2024) The mitogen-activated protein kinase network, wired to dynamically function at multiple scales. Curr Opin Cell Biol 88:102368","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"6084_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.molcel.2008.03.025","volume":"30","author":"A H\u00fcbner","year":"2008","unstructured":"H\u00fcbner A, Barrett T, Flavell RA, Davis RJ (2008) Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30(4):415\u2013425","journal-title":"Mol Cell"},{"issue":"2","key":"6084_CR60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncb1676","volume":"10","author":"J-Y Yang","year":"2008","unstructured":"Yang J-Y, Zong CS, Xia W et al (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138\u2013148","journal-title":"Nat Cell Biol"},{"issue":"3","key":"6084_CR61","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","volume":"79","author":"MJ Boucher","year":"2000","unstructured":"Boucher MJ, Morisset J, Vachon PH, Reed JC, Lain\u00e9 J, Rivard N (2000) MEK\/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79(3):355\u2013369","journal-title":"J Cell Biochem"},{"key":"6084_CR62","doi-asserted-by":"crossref","unstructured":"Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic Okadaic acid or taxol\u2019Oncogene. 23(31):5301\u20135315","DOI":"10.1038\/sj.onc.1207692"},{"issue":"12","key":"6084_CR63","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar AA, Poulikakos PI (2014) Targeting RAS-ERK signaling in cancer: promises and challenges. Nat Rev Drug Discov 13(12):928\u2013942","journal-title":"Nat Rev Drug Discov"},{"issue":"44","key":"6084_CR64","doi-asserted-by":"publisher","first-page":"E5936","DOI":"10.1073\/pnas.1516319112","volume":"112","author":"H Chen","year":"2015","unstructured":"Chen H, Guo R, Zhang Q et al (2015) Erk signaling is indispensable for genomic stability and self-renewal of mouse embryonic stem cells. Proc Natl Acad Sci U S A 112(44):E5936-5943","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"6084_CR65","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.4161\/cc.8.8.8147","volume":"8","author":"Y Mebratu","year":"2009","unstructured":"Mebratu Y, Tesfaigzi Y (2009) How ERK1\/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle Georget Tex 8(8):1168\u20131175","journal-title":"Cell Cycle Georget Tex"},{"issue":"8","key":"6084_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082980","volume":"21","author":"ML Hartman","year":"2020","unstructured":"Hartman ML (2020) Non-apoptotic cell death signaling pathways in melanoma. Int J Mol Sci 21(8):2980","journal-title":"Int J Mol Sci"},{"issue":"8","key":"6084_CR67","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537\u2013549","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"6084_CR68","first-page":"557","volume":"11","author":"AJ Dooley","year":"2016","unstructured":"Dooley AJ, Gupta A, Middleton MR (2016) Ongoing response in BRAF V600E-mutant melanoma after cessation of intermittent vemurafenib therapy: a case. Report\u2019Target Oncol 11(4):557\u2013563","journal-title":"Report\u2019Target Oncol"},{"key":"6084_CR69","doi-asserted-by":"crossref","unstructured":"Sugiura R, Satoh R, Takasaki T (2021) ERK: A Double-Edged sword in Cancer. ERK-Dependent apoptosis as a potential therapeutic strategy for Cancer\u2019Cells. 10(10):2509","DOI":"10.3390\/cells10102509"},{"issue":"1","key":"6084_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 8(1):455","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"6084_CR71","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1002\/jcb.27052","volume":"119","author":"L Hong","year":"2018","unstructured":"Hong L, Wang Y, Chen W, Yang S (2018) MicroRNA-508 suppresses epithelial-mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1\/ERK signaling pathway. J Cell Biochem 119(9):7431\u20137440","journal-title":"J Cell Biochem"},{"issue":"1","key":"6084_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103\u2013119","journal-title":"Expert Opin Ther Targets"},{"issue":"6700","key":"6084_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0850","volume":"384","author":"JE Klomp","year":"2024","unstructured":"Klomp JE, Diehl JN, Klomp JA et al (2024) Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science 384(6700):eadk0850","journal-title":"Science"},{"issue":"6700","key":"6084_CR74","first-page":"eadk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, Klomp JE, Stalnecker CA et al (2024) Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. \u2019Science 384(6700):eadk0775","journal-title":"\u2019Science"},{"issue":"7","key":"6084_CR75","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL (2016) RAS isoforms and mutations in cancer at a glance. J Cell Sci 129(7):1287\u20131292","journal-title":"J Cell Sci"},{"issue":"1","key":"6084_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17(1):58","journal-title":"Mol Cancer"},{"issue":"1","key":"6084_CR77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/cac2.12005","volume":"40","author":"H Liu","year":"2020","unstructured":"Liu H, Zhang B, Sun Z (2020) Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun 40(1):43\u201359","journal-title":"Cancer Commun"},{"issue":"3","key":"6084_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10911-011-9221-5","volume":"16","author":"JP Reddy","year":"2011","unstructured":"Reddy JP, Li Y (2011) Oncogene-induced senescence and its role in tumor suppression. J Mammary Gland Biol Neoplasia 16(3):247\u2013256","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"6084_CR79","doi-asserted-by":"crossref","unstructured":"Marabese M, Ganzinelli M, Garassino MC et al (2015) KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy\u2019Oncotarget. 6(32):34014\u201334022","DOI":"10.18632\/oncotarget.5607"},{"issue":"1","key":"6084_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02025-2","volume":"40","author":"S Kundu","year":"2021","unstructured":"Kundu S, Ali MA, Handin N et al (2021) Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis. J Exp Clin Cancer Res 40(1):225","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"6084_CR81","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee J-M, Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120(22):3446\u20133456","journal-title":"Cancer"},{"issue":"9","key":"6084_CR82","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","volume":"41","author":"J Mo","year":"2022","unstructured":"Mo J, Moye SL, McKay RM, Le LQ (2022) Neurofibromin and suppression of tumorigenesis: beyond the GAP. Oncogene 41(9):1235\u20131251","journal-title":"Oncogene"},{"issue":"1","key":"6084_CR83","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","volume":"10","author":"Y Song","year":"2023","unstructured":"Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X (2023) Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes Dis 10(1):76\u201388","journal-title":"Genes Dis"},{"issue":"5","key":"6084_CR84","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593\u2013602","journal-title":"Cell"},{"issue":"7051","key":"6084_CR85","first-page":"660","volume":"436","author":"M Braig","year":"2005","unstructured":"Braig M, Lee S, Loddenkemper C et al (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. \u2019Nature 436(7051):660\u2013665","journal-title":"\u2019Nature"},{"issue":"6","key":"6084_CR86","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1158\/0008-5472.CAN-05-4006","volume":"66","author":"M Braig","year":"2006","unstructured":"Braig M, Schmitt CA (2006) Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 66(6):2881\u20132884","journal-title":"Cancer Res"},{"key":"6084_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2020.111229","volume":"187","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blake S, Kusuma FK, Pearson RB, Kang J, Chan KT (2020) Oncogene-induced senescence: from biology to therapy. Mech Ageing Dev 187:111229","journal-title":"Mech Ageing Dev"},{"issue":"5","key":"6084_CR88","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/1541-7786.MCR-21-0767","volume":"20","author":"K Dutchak","year":"2022","unstructured":"Dutchak K, Garnett S, Nicoll M, de Bruyns A, Dankort D (2022) MOB3A bypasses BRAF and RAS oncogene-induced senescence by engaging the Hippo pathway. Mol Cancer Res MCR 20(5):770\u2013781","journal-title":"Mol Cancer Res MCR"},{"issue":"10","key":"6084_CR89","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/aps.2017.198","volume":"39","author":"X-L Liu","year":"2018","unstructured":"Liu X-L, Ding J, Meng L-H (2018) Oncogene-induced senescence: a double edged sword in cancer. Acta Pharmacol Sin 39(10):1553\u20131558","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"6084_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/path.5097","volume":"246","author":"VG Gorgoulis","year":"2018","unstructured":"Gorgoulis VG, Pefani D-E, Pateras IS, Trougakos IP (2018) Integrating the DNA damage and protein stress responses during cancer development and treatment. J Pathol 246(1):12\u201340","journal-title":"J Pathol"},{"issue":"12","key":"6084_CR91","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"J-P Copp\u00e9","year":"2008","unstructured":"Copp\u00e9 J-P, Patil CK, Rodier F et al (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853\u20132868","journal-title":"PLoS Biol"},{"issue":"16","key":"6084_CR92","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/emboj\/cdg417","volume":"22","author":"CM Beaus\u00e9jour","year":"2003","unstructured":"Beaus\u00e9jour CM, Krtolica A, Galimi F et al (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22(16):4212\u20134222","journal-title":"EMBO J"},{"issue":"2","key":"6084_CR93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41418-019-0384-8","volume":"27","author":"KT Chan","year":"2020","unstructured":"Chan KT, Blake S, Zhu H et al (2020) A functional genetic screen defines the AKT-induced senescence signaling network. Cell Death Differ 27(2):725\u2013741","journal-title":"Cell Death Differ"},{"issue":"5","key":"6084_CR94","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/path.6164","volume":"260","author":"K Evangelou","year":"2023","unstructured":"Evangelou K, Belogiannis K, Papaspyropoulos A, Petty R, Gorgoulis VG (2023) Escape from senescence: molecular basis and therapeutic ramifications. J Pathol 260(5):649\u2013665","journal-title":"J Pathol"},{"issue":"3","key":"6084_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030420","volume":"10","author":"M Mijit","year":"2020","unstructured":"Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A (2020) Role of p53 in the regulation of cellular senescence. Biomolecules 10(3):420","journal-title":"Biomolecules"},{"key":"6084_CR96","doi-asserted-by":"crossref","unstructured":"Gorgoulis V, Adams PD, Alimonti A et al (2019) \u2018Cellular Senescence: Defining a Path Forward\u2019Cell, 179, (4), pp. 813\u2013827","DOI":"10.1016\/j.cell.2019.10.005"},{"issue":"5","key":"6084_CR97","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/febs.16381","volume":"290","author":"M Takasugi","year":"2023","unstructured":"Takasugi M, Yoshida Y, Hara E, Ohtani N (2023) The role of cellular senescence and SASP in tumour microenvironment. FEBS J 290(5):1348\u20131361","journal-title":"FEBS J"},{"issue":"8","key":"6084_CR98","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1101\/gad.203984.112","volume":"27","author":"X Desch\u00eanes-Simard","year":"2013","unstructured":"Desch\u00eanes-Simard X, Gaumont-Leclerc M-F, Bourdeau V et al (2013) Tumor suppressor activity of the ERK\/MAPK pathway by promoting selective protein degradation. Genes Dev 27(8):900\u2013915","journal-title":"Genes Dev"},{"key":"6084_CR99","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan EA, Wallis R, Mossa F, Bishop CL (2024) The paradox of senescent-marker positive cancer cells: challenges and opportunities\u2019Npj aging. 10(1):41","DOI":"10.1038\/s41514-024-00168-y"},{"key":"6084_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1045521","volume":"12","author":"A Stulpinas","year":"2022","unstructured":"Stulpinas A, Sereika M, Vitkeviciene A, Imbrasaite A, Krestnikova N, Kalvelyte AV (2022) Crosstalk between protein kinases AKT and ERK1\/2 in human lung tumor-derived cell models. Front Oncol 12:1045521","journal-title":"Front Oncol"},{"issue":"1","key":"6084_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02096-7","volume":"23","author":"Z Dong","year":"2024","unstructured":"Dong Z, Luo Y, Yuan Z, Tian Y, Jin T, Xu F (2024) Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer 23(1):181","journal-title":"Mol Cancer"},{"issue":"1","key":"6084_CR102","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI831","volume":"101","author":"RK Ravi","year":"1998","unstructured":"Ravi RK, Weber E, McMahon M et al (1998) Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101(1):153\u2013159","journal-title":"J Clin Invest"},{"issue":"4","key":"6084_CR103","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1165\/ajrcmb.20.4.3406","volume":"20","author":"RK Ravi","year":"1999","unstructured":"Ravi RK, Thiagalingam A, Weber E, McMahon M, Nelkin BD, Mabry M (1999) Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. Am J Respir Cell Mol Biol 20(4):543\u2013549","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"6084_CR104","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C","volume":"72","author":"RK Ravi","year":"1999","unstructured":"Ravi RK, McMahon M, Yangang Z et al (1999) Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem 72(4):458\u2013469","journal-title":"J Cell Biochem"},{"issue":"2","key":"6084_CR105","first-page":"639","volume":"9","author":"VP Stanton","year":"1989","unstructured":"Stanton VP, Nichols DW, Laudano AP, Cooper GM (1989) Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol 9(2):639\u2013647","journal-title":"Mol Cell Biol"},{"issue":"10","key":"6084_CR106","first-page":"6241","volume":"13","author":"ML Samuels","year":"1993","unstructured":"Samuels ML, Weber MJ, Bishop JM, McMahon M (1993) Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol 13(10):6241\u20136252","journal-title":"Mol Cell Biol"},{"issue":"22","key":"6084_CR107","doi-asserted-by":"publisher","first-page":"18871","DOI":"10.1074\/jbc.M011514200","volume":"276","author":"CP Fanton","year":"2001","unstructured":"Fanton CP, McMahon M, Pieper RO (2001) Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation *. J Biol Chem 276(22):18871\u201318877","journal-title":"J Biol Chem"},{"issue":"2","key":"6084_CR108","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/MCB.23.2.543-554.2003","volume":"23","author":"J-I Park","year":"2003","unstructured":"Park J-I, Strock CJ, Ball DW, Nelkin BD (2003) The Ras\/Raf\/MEK\/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor\/JAK\/STAT pathway. Mol Cell Biol 23(2):543\u2013554","journal-title":"Mol Cell Biol"},{"issue":"48","key":"6084_CR109","doi-asserted-by":"publisher","first-page":"33006","DOI":"10.1074\/jbc.M109.012591","volume":"284","author":"S-K Hong","year":"2009","unstructured":"Hong S-K, Yoon S, Moelling C, Arthan D, Park J-I (2009) Noncatalytic function of ERK1\/2 can promote Raf\/MEK\/ERK-mediated growth arrest signaling *. J Biol Chem 284(48):33006\u201333018","journal-title":"J Biol Chem"},{"issue":"18","key":"6084_CR110","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.yexcr.2011.08.008","volume":"317","author":"S-K Hong","year":"2011","unstructured":"Hong S-K, Kim J-H, Lin M-F, Park J-I (2011) The Raf\/MEK\/extracellular signal-regulated kinase 1\/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res 317(18):2671\u20132682","journal-title":"Exp Cell Res"},{"issue":"7","key":"6084_CR111","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jcp.24521","volume":"229","author":"J-P Gu\u00e9gan","year":"2014","unstructured":"Gu\u00e9gan J-P, Ezan F, Gailhouste L, Langou\u00ebt S, Baffet G (2014) MEK1\/2 overactivation can promote growth arrest by mediating ERK1\/2-dependent phosphorylation of p70S6K. J Cell Physiol 229(7):903\u2013915","journal-title":"J Cell Physiol"},{"key":"6084_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cellsig.2017.10.001","volume":"42","author":"S-K Hong","year":"2018","unstructured":"Hong S-K, Wu P-K, Park J-I (2018) A cellular threshold for active ERK1\/2 levels determines Raf\/MEK\/ERK-mediated growth arrest versus death responses. Cell Signal 42:11\u201320","journal-title":"Cell Signal"},{"issue":"3","key":"6084_CR113","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/0008-5472.CAN-16-2925","volume":"77","author":"M Drosten","year":"2017","unstructured":"Drosten M, Sim\u00f3n-Carrasco L, Hern\u00e1ndez-Porras I et al (2017) H-Ras and K-Ras oncoproteins induce different tumor spectra when driven by the same regulatory sequences. Cancer Res 77(3):707\u2013718","journal-title":"Cancer Res"},{"key":"6084_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103224","author":"R Caeser","year":"2021","unstructured":"Caeser R, Hulton C, Costa E (2021) MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. iScience. https:\/\/doi.org\/10.1016\/j.isci.2021.103224","journal-title":"iScience"},{"key":"6084_CR115","doi-asserted-by":"crossref","unstructured":"Inoue Y, Nikolic A, Farnsworth D et al (2021) Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer\u2019eLife. 10:e66524","DOI":"10.7554\/eLife.66524"},{"issue":"6","key":"6084_CR116","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/febs.13197","volume":"282","author":"P-K Wu","year":"2015","unstructured":"Wu P-K, Hong S-K, Yoon S-H, Park J-I (2015) Active ERK2 is sufficient to mediate growth arrest and differentiation signaling. FEBS J 282(6):1017\u20131030","journal-title":"FEBS J"},{"issue":"20","key":"6084_CR117","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1128\/MCB.00021-13","volume":"33","author":"P-K Wu","year":"2013","unstructured":"Wu P-K, Hong S-K, Veeranki S et al (2013) A mortalin\/HSPA9-mediated switch in tumor-suppressive signaling of Raf\/MEK\/extracellular signal-regulated kinase. Mol Cell Biol 33(20):4051\u20134067","journal-title":"Mol Cell Biol"},{"issue":"23","key":"6084_CR118","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1158\/0008-5472.CAN-14-2073","volume":"74","author":"EM Goetz","year":"2014","unstructured":"Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA (2014) ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res 74(23):7079\u20137089","journal-title":"Cancer Res"},{"issue":"4","key":"6084_CR119","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.celrep.2016.09.061","volume":"17","author":"L Brenan","year":"2016","unstructured":"Brenan L, Andreev A, Cohen O et al (2016) Phenotypic characterization of a comprehensive set of MAPK1\/ERK2 missense mutants. Cell Rep 17(4):1171\u20131183","journal-title":"Cell Rep"},{"issue":"1","key":"6084_CR120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","volume":"17","author":"GP Leung","year":"2019","unstructured":"Leung GP, Feng T, Sigoillot FD et al (2019) Hyperactivation of MAPK signaling is deleterious to RAS\/RAF-mutant melanoma. Mol Cancer Res 17(1):199\u2013211","journal-title":"Mol Cancer Res"},{"issue":"10","key":"6084_CR121","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41588-023-01515-7","volume":"55","author":"L Chang","year":"2023","unstructured":"Chang L, Jung NY, Atari A et al (2023) Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nat Genet 55(10):1709\u20131720","journal-title":"Nat Genet"},{"key":"6084_CR122","doi-asserted-by":"crossref","unstructured":"Soudah N, Baskin A, Darash-Yahana M et al (2025) \u2018Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop\u2019Oncogene, pp. 1\u201326","DOI":"10.1038\/s41388-025-03437-6"},{"key":"6084_CR123","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcdb.2016.01.009","volume":"50","author":"AM Kidger","year":"2016","unstructured":"Kidger AM, Keyse SM (2016) The regulation of oncogenic Ras\/ERK signaling by dual-specificity mitogen activated protein kinase phosphatases (MKPs). Semin Cell Dev Biol 50:125\u2013132","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"6084_CR124","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ncb1398","volume":"8","author":"S Rahmouni","year":"2006","unstructured":"Rahmouni S, Cerignoli F, Alonso A et al (2006) Loss of the VHR dual-specific phosphatase causescell-cycle arrest and senescence. Nat Cell Biol 8(5):524\u2013531","journal-title":"Nat Cell Biol"},{"issue":"3","key":"6084_CR125","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cellsig.2015.01.005","volume":"27","author":"M Karkhanis","year":"2015","unstructured":"Karkhanis M, Park J-I (2015) Sp1 regulates Raf\/MEK\/ERK-induced p21CIP1 transcription in TP53-mutated cancer cells. Cell Signal 27(3):479\u2013486","journal-title":"Cell Signal"},{"issue":"18","key":"6084_CR126","doi-asserted-by":"publisher","first-page":"e00061","DOI":"10.1128\/MCB.00061-17","volume":"37","author":"P-K Wu","year":"2017","unstructured":"Wu P-K, Hong S-K, Park J-I (2017) Steady-state levels of phosphorylated mitogen-activated protein kinase kinase 1\/2 determined by mortalin\/HSPA9 and protein phosphatase 1 alpha in KRAS and BRAF tumor cells. Mol Cell Biol 37(18):e00061-17","journal-title":"Mol Cell Biol"},{"key":"6084_CR127","doi-asserted-by":"crossref","unstructured":"Wu P-K, Hong S-K, Starenki D et al (2020) Mortalin\/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability\u2019Oncogene. 39(21):4257\u20134270","DOI":"10.1038\/s41388-020-1285-5"},{"issue":"622","key":"6084_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay1478","volume":"13","author":"P-K Wu","year":"2020","unstructured":"Wu P-K, Hong S-K, Chen W et al (2020) Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability. Sci Signal 13(622):eaay1478","journal-title":"Sci Signal"},{"key":"6084_CR129","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2020.12.044","volume":"502","author":"P-K Wu","year":"2021","unstructured":"Wu P-K, Hong S-K, Park J-I (2021) Mortalin depletion induces MEK\/ERK-dependent and ANT\/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells. Cancer Lett 502:25\u201333","journal-title":"Cancer Lett"},{"key":"6084_CR130","doi-asserted-by":"crossref","unstructured":"Ingram K, Samson SC, Zewdu R, Zitnay RG, Snyder EL, Mendoza MC (2022) NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity\u2019Oncogene. 41(2):293\u2013300","DOI":"10.1038\/s41388-021-02076-x"},{"key":"6084_CR131","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202101235","author":"N Gutierrez-Prat","year":"2022","unstructured":"Gutierrez-Prat N, Zuberer HL, Mangano L et al (2022) DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Life Sci Alliance. https:\/\/doi.org\/10.26508\/lsa.202101235","journal-title":"Life Sci Alliance"},{"key":"6084_CR132","unstructured":"Valcikova B, Vadovicova N, Smolkova K et al \u2018eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations\u2019Proc. Natl. Acad. Sci. U. S. A., no date, 121, (44), p. e2321305121"},{"issue":"7516","key":"6084_CR133","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature13572","volume":"513","author":"L Boussemart","year":"2014","unstructured":"Boussemart L, Malka-Mahieu H, Girault I et al (2014) eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513(7516):105\u2013109","journal-title":"Nature"},{"key":"6084_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13360-6","volume":"10","author":"S Shen","year":"2019","unstructured":"Shen S, Faouzi S, Bastide A et al (2019) An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat Commun 10:5713","journal-title":"Nat Commun"},{"issue":"12","key":"6084_CR135","first-page":"4619","volume":"31","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Sonobe M, Takahashi T et al (2011) Clinical significance of BRAF gene mutations in patients with Non-small cell lung. Cancer\u2019Anticancer Res 31(12):4619\u20134623","journal-title":"Cancer\u2019Anticancer Res"},{"issue":"5","key":"6084_CR136","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1309\/AJCPBS85VJEOBPDO","volume":"131","author":"R De Oliveira Duarte Achcar","year":"2009","unstructured":"De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA (2009) Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 131(5):694\u2013700","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"6084_CR137","first-page":"347","volume":"39","author":"RK Thomas","year":"2007","unstructured":"Thomas RK, Baker AC, DeBiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. \u2019Nat Genet 39(3):347\u2013351","journal-title":"\u2019Nat Genet"},{"issue":"1","key":"6084_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-406","volume":"11","author":"E Borr\u00e0s","year":"2011","unstructured":"Borr\u00e0s E, Jurado I, Hernan I et al (2011) Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 11(1):406","journal-title":"BMC Cancer"},{"key":"6084_CR139","doi-asserted-by":"crossref","unstructured":"Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin S-Q, Varmus H (2015) Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma\u2019eLife. 4:e06907","DOI":"10.7554\/eLife.06907"},{"issue":"1","key":"6084_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39608-2","volume":"13","author":"M Sinkala","year":"2023","unstructured":"Sinkala M (2023) Mutational landscape of cancer-driver genes across human cancers. Sci Rep 13(1):12742","journal-title":"Sci Rep"},{"key":"6084_CR141","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/sqb.2016.81.030866","volume":"81","author":"H Varmus","year":"2016","unstructured":"Varmus H, Unni AM, Lockwood WW (2016) How cancer genomics drives cancer biology: does synthetic lethality explain mutually exclusive oncogenic mutations? Cold Spring Harb Symp Quant Biol 81:247\u2013255","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"8","key":"6084_CR142","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1096\/fj.08-108985","volume":"22","author":"C-H Yeang","year":"2008","unstructured":"Yeang C-H, McCormick F, Levine A (2008) Combinatorial patterns of somatic gene mutations in cancer. FASEB J 22(8):2605\u20132622","journal-title":"FASEB J"},{"issue":"16","key":"6084_CR143","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/onc.2016.385","volume":"36","author":"C Ambrogio","year":"2017","unstructured":"Ambrogio C, Barbacid M, Santamar\u00eda D (2017) In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene 36(16):2309\u20132318","journal-title":"Oncogene"},{"issue":"10","key":"6084_CR144","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/onc.2015.186","volume":"35","author":"J Cisowski","year":"2016","unstructured":"Cisowski J, Sayin VI, Liu M, Karlsson C, Bergo MO (2016) Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene 35(10):1328\u20131333","journal-title":"Oncogene"},{"issue":"13","key":"6084_CR145","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-05-4671","volume":"66","author":"C Petti","year":"2006","unstructured":"Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M (2006) Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 66(13):6503\u20136511","journal-title":"Cancer Res"},{"issue":"1","key":"6084_CR146","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/pcmr.12919","volume":"34","author":"E Christodoulou","year":"2021","unstructured":"Christodoulou E, Rashid M, Pacini C et al (2021) Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma. Pigment Cell Melanoma Res 34(1):122\u2013131","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"6084_CR147","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG et al (2017) Defining a cancer dependency map. Cell 170(3):564-576.e16","journal-title":"Cell"},{"issue":"9","key":"6084_CR148","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.jid.2022.02.007","volume":"142","author":"H Kamada","year":"2022","unstructured":"Kamada H, Yasuhira S, Shibazaki M, Amano H, Maesawa C (2022) DUSP4 inactivation leads to reduced extracellular signal\u2012regulated kinase activity through upregulation of DUSP6 in melanoma cells. J Invest Dermatol 142(9):2499-2507e.e6","journal-title":"J Invest Dermatol"},{"issue":"13","key":"6084_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108928","volume":"34","author":"E Cho","year":"2021","unstructured":"Cho E, Lou HJ, Kuruvilla L, Calderwood DA, Turk BE (2021) PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. Cell Rep 34(13):108928","journal-title":"Cell Rep"},{"issue":"6","key":"6084_CR150","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","volume":"22","author":"AC Seghers","year":"2012","unstructured":"Seghers AC, Wilgenhof S, Lebb\u00e9 C, Neyns B (2012) Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 22(6):466","journal-title":"Melanoma Res"},{"issue":"20","key":"6084_CR151","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-13-0661","volume":"19","author":"E Romano","year":"2013","unstructured":"Romano E, Pradervand S, Paillusson A et al (2013) Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 19(20):5749\u20135757","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6084_CR152","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/2159-8290.CD-13-1038","volume":"4","author":"O Abdel-Wahab","year":"2014","unstructured":"Abdel-Wahab O, Klimek VM, Gaskell AA et al (2014) Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov 4(5):538\u2013545","journal-title":"Cancer Discov"},{"issue":"6","key":"6084_CR153","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000196","volume":"25","author":"J Roux","year":"2015","unstructured":"Roux J, Pages C, Malouf D et al (2015) BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Res 25(6):559","journal-title":"Melanoma Res"},{"issue":"12","key":"6084_CR154","volume":"7","author":"T Jain","year":"2015","unstructured":"Jain T, Bryce A (2015) Intermittent BRAF inhibition can achieve prolonged disease control in BRAF mutant melanoma. Cureus 7(12):e410","journal-title":"Cureus"},{"issue":"3","key":"6084_CR155","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/CMR.0000000000000350","volume":"27","author":"C Desvignes","year":"2017","unstructured":"Desvignes C, Rached A, Templier H (2017) BRAF inhibitor discontinuation and Rechallenge in advanced melanoma patients with a complete initial treatment response. \u2019Melanoma Res 27(3):281","journal-title":"\u2019Melanoma Res"},{"issue":"1","key":"6084_CR156","first-page":"724","volume":"3","author":"H Shi","year":"2012","unstructured":"Shi H, Moriceau G, Kong X et al (2012) Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance\u2019Nat. Commun 3(1):724","journal-title":"Commun"},{"issue":"7326","key":"6084_CR157","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) Inhibition by RTK or N-RAS upregulation. Nature 468(7326):973\u2013977","journal-title":"Nature"},{"issue":"7494","key":"6084_CR158","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S et al (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508(7494):118\u2013122","journal-title":"Nature"},{"key":"6084_CR159","doi-asserted-by":"crossref","unstructured":"Moriceau G, Hugo W, Hong A et al (2015) Tunable-Combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug Addiction\u2019Cancer cell. 27(2):240\u2013256","DOI":"10.1016\/j.ccell.2014.11.018"},{"issue":"1","key":"6084_CR160","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong A, Moriceau G, Sun L et al (2018) Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discov 8(1):74\u201393","journal-title":"Cancer Discov"},{"issue":"6","key":"6084_CR161","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","volume":"173","author":"L Wang","year":"2018","unstructured":"Wang L, de Oliveira RL, Huijberts S et al (2018) An acquired vulnerability of Drug-Resistant melanoma with therapeutic potential. Cell 173(6):1413\u20131425e14","journal-title":"Cell"},{"issue":"15","key":"6084_CR162","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-23-3171","volume":"30","author":"A Embaby","year":"2024","unstructured":"Embaby A, Huijberts SCFA, Wang L et al (2024) A Proof-of-Concept study of sequential treatment with the HDAC inhibitor Vorinostat following BRAF and MEK inhibitors in BRAFV600-Mutated Melanoma\u2019Clin. Cancer Res Off J Am Assoc Cancer Res 30(15):3157\u20133166","journal-title":"Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"6084_CR163","first-page":"292","volume":"76","author":"K Suda","year":"2012","unstructured":"Suda K, Tomizawa K, Osada H et al (2012) Conversion from the oncogene addiction to drug addiction by intensive Inhibition of the EGFR and MET in lung cancer with activating EGFR mutation\u2019Lung. Cancer Amst Neth 76(3):292\u2013299","journal-title":"Cancer Amst Neth"},{"issue":"14","key":"6084_CR164","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1158\/0008-5472.CAN-14-3437","volume":"75","author":"AD Amin","year":"2015","unstructured":"Amin AD, Rajan SS, Liang WS et al (2015) Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK\u2009+\u2009tumors. Cancer Res 75(14):2916\u20132927","journal-title":"Cancer Res"},{"issue":"29","key":"6084_CR165","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1038\/onc.2015.456","volume":"35","author":"M Ceccon","year":"2016","unstructured":"Ceccon M, Merlo MEB, Mologni L et al (2016) Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene 35(29):3854\u20133865","journal-title":"Oncogene"},{"issue":"5","key":"6084_CR166","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s10637-013-9959-2","volume":"31","author":"Y Funakoshi","year":"2013","unstructured":"Funakoshi Y, Mukohara T, Tomioka H et al (2013) Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs 31(5):1158\u20131168","journal-title":"Invest New Drugs"},{"issue":"9","key":"6084_CR167","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nchembio.190","volume":"5","author":"G Molina","year":"2009","unstructured":"Molina G, Vogt A, Bakan A et al (2009) Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 5(9):680\u2013687","journal-title":"Nat Chem Biol"},{"issue":"10","key":"6084_CR168","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/cbic.201402000","volume":"15","author":"VN Korotchenko","year":"2014","unstructured":"Korotchenko VN, Saydmohammed M, Vollmer LL et al (2014) In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem 15(10):1436\u20131445","journal-title":"Chembiochem"},{"issue":"1","key":"6084_CR169","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccell.2015.05.008","volume":"28","author":"S Shojaee","year":"2015","unstructured":"Shojaee S, Caeser R, Buchner M et al (2015) Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28(1):114\u2013128","journal-title":"Cancer Cell"},{"key":"6084_CR170","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2017.10.007","volume":"412","author":"Q-N Wu","year":"2018","unstructured":"Wu Q-N, Liao Y-F, Lu Y-X et al (2018) Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett 412:243\u2013255","journal-title":"Cancer Lett"},{"issue":"13","key":"6084_CR171","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1158\/1078-0432.CCR-18-3224","volume":"25","author":"A Ramkissoon","year":"2019","unstructured":"Ramkissoon A, Chaney KE, Milewski D et al (2019) Targeted inhibition of the dual specificity phosphatases DUSP1 and DUSP6 suppress MPNST growth via JNK. Clin Cancer Res 25(13):4117\u20134127","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6084_CR172","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/1535-7163.MCT-24-0355","volume":"23","author":"A Martin-Vega","year":"2024","unstructured":"Martin-Vega A, Earnest SA, Augustyn A et al (2024) ASCL1 restrains ERK1\/2 to promote survival of a subset of neuroendocrine lung cancers. Mol Cancer Ther 23(12):1789\u20131800","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"6084_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061625","volume":"19","author":"NK Dubey","year":"2018","unstructured":"Dubey NK, Peng B-Y, Lin C-M et al (2018) NSC 95397 suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and the ERK1\/2 pathway. Int J Mol Sci 19(6):1625","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6084_CR174","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1073\/pnas.95.6.3014","volume":"95","author":"CC Franklin","year":"1998","unstructured":"Franklin CC, Srikanth S, Kraft AS (1998) Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A 95(6):3014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6084_CR175","doi-asserted-by":"crossref","unstructured":"Ciccone M, Calin GA, Perrotti D (2015) \u2018From the biology of PP2A to the pads for therapy of hematologic. Malignancies\u2019Front Oncol, 5","DOI":"10.3389\/fonc.2015.00021"},{"issue":"1","key":"6084_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A di Ghelli Luserna Ror\u00e0","year":"2020","unstructured":"di Ghelli Luserna Ror\u00e0 A, Cerchione C, Martinelli G, Simonetti G (2020) A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol 13(1):126","journal-title":"J Hematol Oncol"},{"issue":"5","key":"6084_CR177","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s44319-024-00128-3","volume":"25","author":"MH Dias","year":"2024","unstructured":"Dias MH, Liudkovska V, Montenegro Navarro J et al (2024) The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. EMBO Rep 25(5):2220\u20132238","journal-title":"EMBO Rep"},{"issue":"7","key":"6084_CR178","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/gtc.12499","volume":"22","author":"R Satoh","year":"2017","unstructured":"Satoh R, Hagihara K, Matsuura K et al (2017) Identification of ACA-28, a 1\u2032-acetoxychavicol acetate analogue compound, as a novel modulator of ERK MAPK signaling, which preferentially kills human melanoma cells. Genes Cells 22(7):608\u2013618","journal-title":"Genes Cells"},{"key":"6084_CR179","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/7683793","volume":"2024","author":"T Takasaki","year":"2024","unstructured":"Takasaki T, Hamabe Y, Touchi K et al (2024) ACA-28, an ERK MAPK signaling modulator, exerts anticancer activity through ROS induction in melanoma and pancreatic cancer cells. Oxid Med Cell Longev 2024:7683793","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"6084_CR180","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2008.02.029","volume":"266","author":"JS Clerkin","year":"2008","unstructured":"Clerkin JS, Naughton R, Quiney C, Cotter TG (2008) Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 266(1):30\u201336","journal-title":"Cancer Lett"},{"issue":"5","key":"6084_CR181","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2004.12.041","volume":"120","author":"H Kamata","year":"2005","unstructured":"Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNF\u03b1-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120(5):649\u2013661","journal-title":"Cell"},{"issue":"1","key":"6084_CR182","first-page":"1","volume":"7","author":"G-N Li","year":"2022","unstructured":"Li G-N, Zhao X-J, Wang Z et al (2022) Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. Signal Transduct Target Ther 7(1):1\u201315","journal-title":"Signal Transduct Target Ther"},{"key":"6084_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1012-4","volume":"18","author":"K Xu","year":"2019","unstructured":"Xu K, Park D, Magis AT et al (2019) Small molecule KRAS agonist for mutant KRAS cancer therapy. Mol Cancer 18:85","journal-title":"Mol Cancer"},{"issue":"7","key":"6084_CR184","first-page":"1276","volume":"14","author":"MH Dias","year":"2024","unstructured":"Dias MH, Friskes A, Wang S et al (2024) Paradoxical activation of oncogenic signaling as a cancer treatment. Strategy\u2019Cancer Discov 14(7):1276\u20131301","journal-title":"Strategy\u2019Cancer Discov"},{"issue":"4","key":"6084_CR185","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer M, Jansen Y, Planken S et al (2017) Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 18(4):464\u2013472","journal-title":"Lancet Oncol"},{"issue":"10","key":"6084_CR186","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, Othus M, Daud AI et al (2020) Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med 26(10):1564\u20131568","journal-title":"Nat Med"},{"issue":"1","key":"6084_CR187","first-page":"7008","volume":"12","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao M, Mayo de Las Casas C, Oramas J et al (2021) Intermittent BRAF Inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. \u2019Nat Commun 12(1):7008","journal-title":"\u2019Nat Commun"},{"issue":"13","key":"6084_CR188","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","volume":"23","author":"V Chung","year":"2017","unstructured":"Chung V, Mansfield AS, Braiteh F et al (2017) Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Clin Cancer Res 23(13):3277\u20133284","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6084_CR189","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/15384047.2015.1040961","volume":"16","author":"CS Hong","year":"2015","unstructured":"Hong CS, Ho W, Zhang C, Yang C, Elder JB, Zhuang Z (2015) LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther 16(6):821\u2013833","journal-title":"Cancer Biol Ther"},{"key":"6084_CR190","doi-asserted-by":"crossref","unstructured":"Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin S-Q, Varmus H (2015) \u2018Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma\u2019eLife, 4","DOI":"10.7554\/eLife.06907"},{"issue":"5","key":"6084_CR191","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ccr.2011.04.002","volume":"19","author":"RB Blasco","year":"2011","unstructured":"Blasco RB, Francoz S, Santamar\u00eda D et al (2011) C-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19(5):652\u2013663","journal-title":"Cancer Cell"},{"issue":"48","key":"6084_CR192","doi-asserted-by":"publisher","first-page":"33006","DOI":"10.1074\/jbc.M109.012591","volume":"284","author":"S-K Hong","year":"2009","unstructured":"Hong S-K, Yoon S, Moelling C, Arthan D, Park J-I (2009) Noncatalytic function of ERK1\/2 can promote Raf\/MEK\/ERK-mediated growth arrest signaling. J Biol Chem 284(48):33006\u201333018","journal-title":"J Biol Chem"},{"issue":"1","key":"6084_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s12862-015-0450-x","volume":"15","author":"R Busc\u00e0","year":"2015","unstructured":"Busc\u00e0 R, Christen R, Lovern M et al (2015) ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1. BMC Evol Biol 15(1):179","journal-title":"BMC Evol Biol"},{"issue":"1","key":"6084_CR194","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/MCB.00800-07","volume":"28","author":"R Lefloch","year":"2008","unstructured":"Lefloch R, Pouyss\u00e9gur J, Lenormand P (2008) Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 28(1):511\u2013527","journal-title":"Mol Cell Biol"},{"issue":"12","key":"6084_CR195","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1128\/MCB.00131-10","volume":"30","author":"L Voisin","year":"2010","unstructured":"Voisin L, Saba-El-Leil MK, Julien C, Fr\u00e9min C, Meloche S (2010) Genetic demonstration of a redundant role of extracellular signal-regulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in promoting fibroblast proliferation. Mol Cell Biol 30(12):2918\u20132932","journal-title":"Mol Cell Biol"},{"issue":"4","key":"6084_CR196","first-page":"929","volume":"23","author":"EFA van \u2018t Wout","year":"2014","unstructured":"van \u2018t Wout EFA, Dickens JA, van Schadewijk A et al (2014) Increased ERK signaling promotes inflammatory signaling in primary airway epithelial cells expressing Z \u03b11-antitrypsin\u2019Hum. Mol Genet 23(4):929\u2013941","journal-title":"Mol Genet"},{"key":"6084_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gro\u00df O, Brummer T, Zeiser R (2020) Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun 11:5439","journal-title":"Nat Commun"},{"issue":"9","key":"6084_CR198","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809\u2013819","journal-title":"N Engl J Med"},{"issue":"26","key":"6084_CR199","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"key":"6084_CR200","doi-asserted-by":"crossref","unstructured":"Rasmussen DM, Semonis MM, Greene JT et al (2024) \u2018Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors\u2019eLife, 13, p. RP95481","DOI":"10.7554\/eLife.95481.2"},{"issue":"3","key":"6084_CR201","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors\u2019N. Engl J Med 366(3):207\u2013215","journal-title":"Engl J Med"},{"issue":"1","key":"6084_CR202","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41698-022-00328-x","volume":"6","author":"DA Farnsworth","year":"2022","unstructured":"Farnsworth DA, Inoue Y, Johnson FD et al (2022) MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. NPJ Precis Oncol 6(1):88","journal-title":"NPJ Precis Oncol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06084-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06084-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06084-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:39:08Z","timestamp":1781642348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06084-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":202,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6084"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06084-6","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"184"}}